Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8238138 | 0.90 | USP30 (0.38) | — | |
| SCHEMBL3495602 | 0.89 | CYP11B2 (0.34) | CYP11B2PTGS2HRH3 | |
| SCHEMBL3496018 | 0.83 | CYP11B2 (0.35) | CYP11B2PTGS2HRH3 | |
| SCHEMBL4982236 | 0.82 | HCRTR2 (0.31) | PTGS2HCRTR2 | |
| SCHEMBL3493922 | 0.82 | CYP11B2 (0.34) | CYP11B2PTGS2HRH3 | |
| SCHEMBL3493920 | 0.82 | CYP11B2 (0.34) | CYP11B2PTGS2HRH3 | |
| SCHEMBL4988573 | 0.81 | CYP11B2 (0.36) | CYP11B2PTGS2 | |
| SCHEMBL3494313 | 0.81 | POLB (0.34) | — | |
| SCHEMBL3493884 | 0.77 | CA1 (0.41) | PTGS2 | |
| SCHEMBL13340919 | 0.76 | DRD2 (0.39) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CYP11B2 29/4885PTGS2 865/4885HCRTR2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.